Embecta Corp. (NASDAQ:EMBC) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 0.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,025,483 shares of the company's stock after buying an additional 28,031 shares during the quarter. Vanguard Group Inc. owned approximately 12.09% of Embecta worth $145,076,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its stake in Embecta by 175.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company's stock worth $25,000 after purchasing an additional 774 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Embecta by 5.6% during the fourth quarter. Victory Capital Management Inc. now owns 17,489 shares of the company's stock valued at $361,000 after buying an additional 923 shares during the period. Inspire Advisors LLC raised its holdings in shares of Embecta by 3.7% in the fourth quarter. Inspire Advisors LLC now owns 32,307 shares of the company's stock valued at $667,000 after acquiring an additional 1,138 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Embecta by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 145,269 shares of the company's stock worth $2,048,000 after acquiring an additional 1,600 shares during the period. Finally, Quarry LP bought a new position in Embecta during the 3rd quarter worth about $30,000. 93.83% of the stock is currently owned by institutional investors.

Insider Transactions at Embecta

In other news, Director Milton Mayo Morris sold 3,100 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the sale, the director now directly owns 36,133 shares of the company's stock, valued at $591,858.54. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.42% of the company's stock.

Remove Ads

Embecta Price Performance

Shares of EMBC stock traded up $0.29 during mid-day trading on Friday, hitting $12.30. 559,872 shares of the stock traded hands, compared to its average volume of 453,988. The stock's fifty day moving average is $13.73 and its two-hundred day moving average is $15.98. Embecta Corp. has a 52-week low of $9.93 and a 52-week high of $21.48. The stock has a market cap of $715.05 million, a P/E ratio of 12.30, a P/E/G ratio of 0.78 and a beta of 1.23.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. As a group, equities analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 4.88%. The ex-dividend date of this dividend was Friday, February 28th. Embecta's dividend payout ratio is presently 60.00%.

Analysts Set New Price Targets

Separately, Mizuho began coverage on shares of Embecta in a research report on Thursday. They issued a "neutral" rating and a $15.00 price target for the company.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.